Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692190 | 0.88 | HDAC1 (0.49) | MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL3685557 | 0.87 | MEN1 (0.62) | MEN1KMT2AHDAC1HDAC2HDAC7 | |
| SCHEMBL3642454 | 0.84 | HDAC1 (0.58) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1931909 | 0.83 | MEN1 (0.49) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL4669167 | 0.83 | HDAC1 (0.59) | HDAC1HDAC2HDAC3 | |
| SCHEMBL3643195 | 0.82 | HDAC1 (0.60) | HDAC1HDAC2HDAC3 | |
| SCHEMBL4318022 | 0.82 | HDAC1 (0.58) | HDAC1HDAC2HDAC3 | |
| SCHEMBL4578581 | 0.80 | HDAC1 (0.47) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1067897 | 0.79 | HDAC1 (0.57) | HDAC1HDAC2HDAC3HDAC7 | |
| SCHEMBL1066546 | 0.78 | HDAC1 (0.60) | MEN1KMT2AHDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170076-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009002495-A1 | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | MEN1 2398/4885KMT2A 153/4885HDAC1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.